Regeneron bets on Parabilis platform in $2.3B AHC deal

Version 1

Regeneron said on May 18, 2026, that it has entered a strategic research collaboration with Parabilis Medicines to develop Antibody-Helicon Conjugates, or AHCs, across multiple therapeutic areas in a deal worth up to about $2.3 billion. Under the agreement, Parabilis will receive $125 million upfront, made up of cash and an equity investment, and could earn additional research, development, regulatory, and commercial milestone payments. The companies said the partnership will combine Regeneron’s antibody capabilities with Parabilis’ Helicon peptide platform, which is designed to help drug developers reach intracellular targets that have historically been difficult or impossible to drug. (globenewswire.com)

Why it matters: For veterinary professionals, this is an early but notable signal that large biopharma companies are continuing to invest in next-generation targeted delivery platforms beyond traditional antibody-drug conjugates. While the collaboration is focused on human therapeutics and no veterinary programs were announced, the underlying concept, using an antibody to guide a payload toward hard-to-reach disease targets, could shape future thinking in oncology and other specialty areas that matter in companion animal medicine. It also underscores how much value investors and drugmakers now place on platforms that promise access to so-called undruggable proteins. (globenewswire.com)

What to watch: Watch for the companies to disclose initial targets, therapeutic areas, or preclinical data that show whether AHCs can deliver on the promise of reaching intracellular proteins at useful selectivity and safety. (globenewswire.com)